MR
AI methods for precision therapies
Developing AI methods for heterogeneity-aware precision therapies.
Overview
Our hope is that building tumor ecosystem representations and understanding the associated heterogeneity will allow us to predict disease progression and treatment response.
PROMETEX: metabolically-instructed therapy selection for prostate cancer
Together with Prof. Marianna Kruithof-de Julio from the Urogenus lab of the University of Bern and Prof. Theodore Alexandrov, Team Leader at EMBL Heidelberg, we are working on combining patient-derived organoids with single-cell metabolomics towards developing metabolically-instructed personalized prostate cancer therapies. Our project PROMETEX was recently awarded a Sinergia grant from the Swiss National Science Foundation.
Contributors
Related projects
Quantifying biological heterogeneity from single-cell data
Understanding, modeling and quantifying different sources of heterogeneity from single-cell measurements.
AI for single-cell research
Understanding spatiotemporal heterogeneity across different scales of biological organization.
Modeling the 4D genome
Modeling the 4D genome with deep learning and stochastic simulations.
Modeling spatial heterogeneity of the tumor microenvironment
Combining spatial single-cell omics with AI to model the complexity of the tumor micorenvironment and enable novel spatial biomarker discovery.